Treatment and prevention of HIV infection with long-acting antiretrovirals

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Expert Review of Clinical Pharmacology

• Publication date

  2018-03-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17512433.2018.1453805PMID 29595351
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy

  2018cited by this paper
• Universal antiretroviral regimens: thinking beyond one-pill-once-a-day

  2017cited by this paper
• Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis.

  2017cited by this paper
• Long‐acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short‐acting methods: a randomized patient preference trial

  2017cited by this paper
• Long-term durability of HIV viral load suppression.

  2017cited by this paper
• Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study

  2017cited by this paper
• Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.

  2017cited by this paper
• Long-acting cabotegravir for prevention: hope versus reality.

  2017influential reference
• Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.

  2017influential reference
• Transmission of Multi-Drug Resistant HIV-1 Despite Antiretroviral Prophylaxis.

  2017cited by this paper
• A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol

  2017cited by this paper
• Long-acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient's perspective.

  2017cited by this paper
• Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission

  2017cited by this paper
• Dual antiretroviral therapy for HIV infection

  2017cited by this paper
• Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults

  2017cited by this paper
• Are we nearing the end in the fight against hepatitis C?

  2017cited by this paper
• "It's inside my body and it's mine".

  2017cited by this paper
• Long-acting slow effective release antiretroviral therapy

  2017influential reference
• Long-Acting HIV Treatment and Prevention: Closer to the Threshold

  2017cited by this paper
• Long-Acting Injectable Antiretroviral Therapy: An Opportunity to Improve Human Immunodeficiency Virus (HIV) Treatment and Reduce HIV Transmission Among Persons Being Released From Prison Facilities.

  2017cited by this paper
• Towards control of the global HIV epidemic: Addressing the middle-90 challenge in the UNAIDS 90–90–90 target

  2017cited by this paper
• In Vitro Cross-Resistance Profiles of Rilpivirine, Dapivirine, and MIV-150, Nonnucleoside Reverse Transcriptase Inhibitor Microbicides in Clinical Development for the Prevention of HIV-1 Infection

  2017cited by this paper
• Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

  2017cited by this paper
• Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.

  2016influential reference
• Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women.

  2016cited by this paper
• HIV-1 drug resistance and resistance testing.

  2016cited by this paper
• A Cure for HIV Infection: “Not in My Lifetime” or “Just Around the Corner”?

  2016cited by this paper
• The promise and pitfalls of long-acting injectable agents for HIV prevention

  2016influential reference
• Current status and prospects of HIV treatment.

  2016cited by this paper
• Expanding Access to a New, More Affordable Levonorgestrel Intrauterine System in Kenya: Service Delivery Costs Compared With Other Contraceptive Methods and Perspectives of Key Opinion Leaders

  2016cited by this paper
• Past, Present, and Future Drug Delivery Systems for Antiretrovirals.

  2016cited by this paper
• Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

  2016cited by this paper
• An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection

  2016cited by this paper
• A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis

  2016cited by this paper
• Creation of a Long-Acting Nanoformulated 2′,3′-Dideoxy-3′-Thiacytidine

  2016cited by this paper
• Ethical considerations regarding oral preexposure prophylaxis in HIV prevention trials

  2016cited by this paper
• Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date

  2016influential reference
• Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial

  2016cited by this paper
• Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA).

  2016cited by this paper
• Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in South Africa: Is There a Will and a Way?

  2016cited by this paper
• Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.

  2016cited by this paper
• Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women

  2016cited by this paper
• Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.

  2016cited by this paper
• Delivery of long-acting injectable antivirals: best approaches and recent advances

  2015cited by this paper
• Formulation and pharmacology of long-acting cabotegravir

  2015cited by this paper
• Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.

  2015influential reference
• Tenofovir-based preexposure prophylaxis for HIV infection among African women.

  2015cited by this paper
• Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

  2015cited by this paper
• Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

  2015cited by this paper
• The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge

  2015cited by this paper
• On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

  2015cited by this paper
• Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

  2015cited by this paper
• Long-acting rilpivirine for HIV prevention

  2015cited by this paper
• Perspective: Special delivery for the gut

  2015cited by this paper
• Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis

  2015cited by this paper
• pH-responsive supramolecular polymer gel as an enteric elastomer for use in gastric devices

  2015cited by this paper
• Regulatory challenges in developing long-acting antiretrovirals for treatment and prevention of HIV infection

  2015cited by this paper
• High Interest in a Long-Acting Injectable Formulation of Pre-Exposure Prophylaxis for HIV in Young Men Who Have Sex with Men in NYC: A P18 Cohort Substudy

  2014cited by this paper
• Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults

  2014cited by this paper
• GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects

  2014cited by this paper
• A Compartmental Pharmacokinetic Evaluation of Long‐Acting Rilpivirine in HIV‐Negative Volunteers for Pre‐Exposure Prophylaxis

  2014cited by this paper
• Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.

  2014cited by this paper
• Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials

  2014cited by this paper
• Evaluating the efficacy and safety of a progestin- and estrogen-releasing ethylene vinyl acetate copolymer contraceptive vaginal ring

  2014cited by this paper
• Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus

  2014influential reference
• Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.

  2014cited by this paper
• Mental, Neurological, and Substance Use Disorders in People Living With HIV/AIDS in Low- and Middle-Income Countries

  2014cited by this paper
• Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study

  2013cited by this paper
• Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design.

  2013cited by this paper
• Development of dapivirine vaginal ring for HIV prevention.

  2013cited by this paper
• Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada

  2013cited by this paper
• Adherence Support Approaches in Biomedical HIV Prevention Trials: Experiences, Insights and Future Directions from Four Multisite Prevention Trials

  2013cited by this paper
• Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor

  2013influential reference
• Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

  2013cited by this paper
• Long-acting injectable antiretrovirals for HIV treatment and prevention

  2013cited by this paper
• Are Thai MSM Willing to Take PrEP for HIV Prevention? An Analysis of Attitudes, Preferences and Acceptance

  2013cited by this paper
• Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults

  2013cited by this paper
• Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

  2013cited by this paper
• Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

  2012cited by this paper
• Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

  2012cited by this paper
• Preexposure prophylaxis for HIV infection among African women.

  2012cited by this paper
• Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents

  2012cited by this paper
• Attitudes and Acceptance of Oral and Parenteral HIV Preexposure Prophylaxis among Potential User Groups: A Multinational Study

  2012cited by this paper
• Antiretroviral drugs for pre-exposure prophylaxis of HIV infection.

  2012cited by this paper
• Preexposure Prophylaxis for HIV Prevention

  2011cited by this paper
• Long-Term Efficacy, Safety, and Tolerability of Rilpivirine (RPV, TMC278) in HIV Type 1-Infected Antiretroviral-Naive Patients: Week 192 Results from a Phase IIb Randomized Trial

  2011cited by this paper
• When patients cannot take pills: antiretroviral drug formulations for managing adult HIV infection.

  2011cited by this paper
• Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.

  2010cited by this paper
• Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection.

  2010cited by this paper
• Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

  2010cited by this paper
• Antiretroviral Adherence and Pharmacokinetics: Review of Their Roles in Sustained Virologic Suppression

  2009cited by this paper
• Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor

  2009cited by this paper
• Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir

  2009cited by this paper
• TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

  2009cited by this paper
• Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

  2009cited by this paper
• Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.

  2009cited by this paper
• A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.

  2009cited by this paper
• Challenges in the development of an HIV-1 vaccine

  2008cited by this paper
• Reproductive options for HIV-serodiscordant couples.

  2006cited by this paper
• Adherence to medication.

  2005cited by this paper

• Facilitators and Barriers to Home-Based Long-Acting Injectable Antiretroviral Therapy: Clinician Perspectives from the INVITE-Home Study.

  2026cites this paper
• Two phase 1 studies of safety, tolerability, and pharmacokinetics of an EFdA prodrug (BRII-732) in healthy adult participants

  2025cites this paper
• Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives

  2024cites this paper
• Triple Threat: HDV, HBV, HIV Coinfection.

  2023cites this paper
• Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration

  2023cites this paper
• Characteristics and risk factors for readmission in HIV-infected patients with Talaromyces marneffei infection

  2023cites this paper
• Treatment of hepatitis delta and HIV infection

  2022cites this paper
• Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases.

  2022cites this paper
• Oral antivirals for the prevention and treatment of SARS-CoV-2 infection.

  2022cites this paper
• Long-Acting Formulations for the Prevention and Treatment of Human Immunodeficiency Virus (HIV)-1 Infection: Strategic Leveraging and Integration of Multidisciplinary Knowledge to Advance Public Health.

  2022cites this paper
• Ultra-long-acting (XLA) antivirals for chronic viral hepatitis

  2021cites this paper
• Long-acting antiretrovirals: a new era for the management and prevention of HIV infection

  2021cites this paper
• Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study

  2021cites this paper
• Current Evidence on Dental Implants in HIV-positive Patients

  2021cites this paper
• Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma

  2021cites this paper
• Design and testing of a cabotegravir implant for HIV prevention.

  2020cites this paper
• Tough requirements for new antiretroviral drugs.

  2020cites this paper
• Lessons Learned From Failures and Success Stories of HIV Breakthroughs: Are We Getting Closer to an HIV Cure?

  2020cites this paper
• Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077

  2020cites this paper
• A Year-Long Extended Release Nanoformulated Cabotegravir Prodrug

  2020cites this paper
• COVID-19 Comes 40 Years After AIDS - Any Lesson?

  2020cites this paper
• Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection

  2020cites this paper
• Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications.

  2020cites this paper
• Does HIV infection affect the survival of dental implants? A systematic review and meta-analysis.

  2020cites this paper
• Long-acting antiretroviral therapy

  2020cites this paper
• Advances in hepatitis B therapeutics

  2020cites this paper
• The LAIs Are Coming! Implementation Science Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping Review

  2020cites this paper
• Nanosystems Applied to HIV Infection: Prevention and Treatments

  2020cites this paper
• Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV

  2019cites this paper
• Deducing Mucosal Pharmacokinetics and Pharmacodynamics of the Anti-HIV Molecule Tenofovir from Measurements in Blood

  2019cites this paper
• The PrEP Care Continuum Among Cisgender Women Who Sell Sex and/or Use Drugs Globally: A Systematic Review

  2019cites this paper
• A unique class of lignin derivatives displays broad anti-HIV activity by interacting with the viral envelope.

  2019cites this paper
• 24 Ubiquitination and SUMOylation in HIV Infection : Friends and Foes

  2019cites this paper
• Synthesis of a long acting nanoformulated emtricitabine ProTide.

  2019cites this paper
• Ubiquitination and SUMOylation in HIV Infection: Friends and Foes.

  2019cites this paper
• Occult hepatitis B and HIV infection.

  2019cites this paper
• Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV.

  2019cites this paper
• Physician Mistrust, Medical System Mistrust, and Perceived Discrimination: Associations with HIV Care Engagement and Viral Load

  2019cites this paper
• A three-in-one, long-acting, nanosuspension reformulation of off-patent antiretrovirals for low-income and middle-income countries.

  2018cites this paper
• HIV-1 update 2018

  2018cites this paper
• Oral Vaccine Delivery for Intestinal Immunity—Biological Basis, Barriers, Delivery System, and M Cell Targeting

  2018cites this paper
• HIV drug resistance in low-income and middle-income countries.

  2018cites this paper